Breaking News

Edge Therapeutics, Oakwood Lab Enter Commercial Supply Pact

To support commercial manufacture of EG-1962 for initial product launch and commercialization

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Edge Therapeutics, Inc. has entered into a supply agreement and an amended development agreement with Oakwood Laboratories for the commercial manufacture of EG-1962 for initial product launch and commercialization. EG-1962, an orphan drug with Fast Track product designation by the FDA, is currently in Phase III development for the treatment of aneurysmal subarachnoid hemorrhage (aSAH). “These new agreements are an important step in establishing the supply of EG-1962 for potential commercializ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters